Latest News
BioCryst Shares Slip on New HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO and targets a late-2027 regulatory submission.
BioCryst Shares Slide on HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell nearly 3% in premarket trading following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO.
BioCryst Shares Slip on New Hereditary Angioedema Drug Data
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company reaffirmed its 2026 revenue outlook and plans a Phase 3 filing by late 2027.
Vanguard S&P 500 ETF Slides on Iran Strike Fears, Oil Surge
Vanguard's S&P 500 ETF declined approximately 1% in Monday's premarket trading following military action against Iran, with oil prices jumping 8% and gold futures rising 3.4% as investors sought safety.
Block Shares Retreat After AI-Driven Restructuring Rally
Block shares declined 3.3% to $61.57 in premarket activity Monday, cooling from Friday's 16.8% rally driven by workforce reductions and an improved profit forecast. Morgan Stanley upgraded the stock to Overweight with a $93 target.
Block Shares Retreat After AI-Driven Rally, Analysts Split on Restructuring
Block shares declined 3.3% to $61.57 in premarket activity Monday, cooling from Friday's 16.8% surge driven by restructuring plans. Analysts remain divided on the long-term implications of the company's AI-focused job cuts.
Block Shares Retreat After AI-Driven Rally, Analysts Split on Outlook
Block shares declined 3.3% to $61.57 in premarket activity Monday, cooling from Friday's 16.8% surge driven by workforce reductions and an improved profit outlook. Analysts remain divided on the long-term implications.
Dentsply Sirona Shares Retreat After Analyst Target Hikes, Dividend Cut
Dentsply Sirona shares declined in premarket trading Monday, giving back a portion of Friday's sharp gains, as analysts adjusted targets following quarterly results and the company outlined a major restructuring.
Dentsply Sirona Retreats in Premarket Despite Analyst Target Hikes
Dentsply Sirona stock declined in premarket trading Monday, giving back some of Friday's sharp gains, even as several analysts increased price targets following Q4 results. The company has suspended its dividend and launched a major restructuring plan.
Dentsply Sirona Retreats in Premarket After Analyst Target Hikes
Dentsply Sirona stock declined 2.5% in premarket trading, giving back a portion of its sharp Friday rally, despite several analysts increasing price targets following Q4 results.